<DOC>
	<DOCNO>NCT01805804</DOCNO>
	<brief_summary>Dual chamber pace know induce leave ventricle remodeling may eventually lead heart failure . The investigator aim test hypothesis valsartan start immediately dual chamber pacemaker implantation prevent leave ventricle remodel twelve month long follow comparison placebo . Echocardiographic assessment leave ventricle remodel correlated plasma activity matrix metalloproteinases tissue inhibitor , index functional capacity plasma level NTproBNP distance meter six minute walk test .</brief_summary>
	<brief_title>Valsartan Prevent Left Ventricle Remodeling Pacemaker Patients</brief_title>
	<detailed_description />
	<mesh_term>Ventricular Remodeling</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>inform write consent age ≥ 18 year first time pacemaker implantation trifascicular block , atrioventricular second third degree block leave ventricle ejection fraction ≥ 40 % significant valvular heart disease ischaemic heart disease require revascularization symptomatic hypotension orthostatic disorder pregnancy , breast feeding , child bear potential previous use angiotensin receptor block agent know hypersensitivity valsartan significant liver disorder significant renal disorder , include renal artery stenosis hyperaldosteronism chronic use nonsteroid antiinflammatory drug chronic use lithium salt Patient 's reluctance disability obey protocol and/or follow schedule visit significant disease reduce expect life duration &lt; 12 month participation trial within last 30 day randomization situation would put risk patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>dual chamber pacing , leave ventricle remodeling , valsartan</keyword>
</DOC>